Shortage of paediatric HIV drug raises serious questions over India’s HIV programme
Even while the Indian government and the bureaucratic officials have unanimously said that the India’s HIV programme has been working like an oiled machine since its introduction, the paediatric HIV drug shortage has raised serious doubts over the ambitious program aimed at bringing the dreaded diseases under control. It is learned that the Cipla pharmaceutical manufacturing company, the sole manufacturer of Lopinavir syrup which is considered as the life saver syrup and paediatric friendly syrup and is prescribed as a perfect medicine for the HIV children, has paused the manufacturing of the syrup, citing that the authorities have been not clearing the dues in the payment for the last couple of years. In an effort to let the concerned top political executives understand the difficulties faced by the HIV affected children due to the shortage of life saver drug, a letter, requesting the proper interference of the political executives to wipe out the difficulties, has been written to the Prime Minister Narendra Modi, Finance Minister Arun Jaitley, and Health Minister J P Nadda by the HIV affected children. Around six hundred and thirty-seven children have signed the request letter. With the aid of the proper medication, the period which takes for the transformation of the HIV status to AIDS status can be increased. Experts say that every person has the right to live. The authorities should strive to give all the possible elements to let them enjoy that right, they added. The shortage of paediatric drugs is a huge shame to the India’s ambitious HIV program, they further added.
Photo Courtesy : Google/ images may be subject to copyright